04.09.2014 19:11:58
|
Teva Announces U.S. Launch Of Generic Baraclude Tablets, 0.5mg And 1mg
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) on Thursday announced the launch of the generic equivalent to Baraclude Tablets, 0.5mg and 1mg, in the United States.
Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude Tablets, 0.5mg and 1mg, marketed by Bristol-Myers Squibb Co. (BMY), had annual sales of about $328 million in the United States, according to IMS data as of June 2014.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Nachrichten
Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 15,65 | -1,88% |
|